FIELD: chemistry; biochemistry.
SUBSTANCE: invention relates to biotechnology. Disclosed is an isolated human antibody to NK cells, which binds with each one of KIR2DL1, KIR2DL2 and KIR2DL3, but not with KIR2DS4, and boosts lytic activity of NK cells towards a human target cell which expresses the HLA-C class I molecule. The antibody can be picked out from the repertoire of antibodies based on the ability for cross reaction with at least KIR2DL1 and KIR2DL2/3 and not bind with KIR2DS4, as well as lysis restoration with NK cells which express KIR2DL, Cw3+ or Cw4+ target cells. The method of producing the human antibody to NK cells involves incubation of cells transformed by an expression vector containing nucleic acid which codes said antibody.
EFFECT: invention discloses a pharmaceutical composition and a method of intensifying cytotoxicity of NK cells in cancer patients.
28 cl, 41 dwg, 10 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION AND METHOD FOR CONTROL OF ACTIVITY OF NATURAL KILLER CELLS | 2004 |
|
RU2376315C2 |
| NK CYTOLERGY CONTROL COMPOSITIONS AND METHODS | 2004 |
|
RU2404993C2 |
| METHODS AND COMPOSITIONS FOR IMPROVING EFFECTIVENESS OF ANTIBODY FOR MEDICAL APPLICATION WITH USING COMPOUNDS POTENTIATING NK-CELLS | 2004 |
|
RU2396981C2 |
| ANTIBODIES BOUND TO EXTRACELLULAR DOMAIN OF TYROSINE KINASE RECEPTOR (ALK) | 2007 |
|
RU2460540C2 |
| CANCER TREATMENT USING ANTI-NKG2A AGENTS | 2015 |
|
RU2721271C2 |
| CANCER TREATMENT WITH CHIMERIC CD33 ANTIGEN RECEPTOR | 2015 |
|
RU2747384C2 |
| KIR3DL2 BINDING AGENTS | 2013 |
|
RU2682449C2 |
| NEW BISPECIFIC ANTIGEN-BINDING MOLECULES WITH CAPABILITY OF SPECIFICALLY BINDING TO CD40 AND FAP | 2018 |
|
RU2766234C2 |
| ANTIBODIES BINDING TO HLA-A2/WT1 | 2018 |
|
RU2815176C2 |
| CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND THEIR USE | 2018 |
|
RU2780020C2 |
